Is a complete FATE research report available?

No complete published report is available for Fate Therapeutics, Inc. (FATE) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Fate Therapeutics, Inc. (FATE)

NASDAQ: FATE · USD

$2.41

-0.11 (-4.4%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-25 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first FATE analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	280.9M
Revenue (ttm)	6.3M
Net income (ttm)	-129.9M
EPS (ttm)	-$1.09
Shares out	116.6M
Volume	1,044,434
Beta	2.52
Price target	$5.41	+124.5%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 6.3M
Net income (ttm): -129.9M
EPS (ttm): -$1.09
Market cap: 280.9M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All FATE indicators

Market & fundamental data

Available fields

209

Groups with data

Currency

USD

Showing 209 of 209 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001434316
Company name	Fate Therapeutics, Inc.
Country	United States
Country code	US
Cusip	31189P102
Employees	161
Employees Change	-20%
Employees Change Percent	-11.05
Enterprise value	$182.9M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2013-10-01
Isin	US31189P1021
Last refreshed	2026-07-25
Market cap	$280.9M
Market cap category	Micro-Cap
Price	$2.41
Price currency	USD
Rev Per Employee	39,229.81x
Sector	Healthcare
Sector PE	44.8
Sector PE Fwd	23.59
Sic	2836
Symbol	FATE
Website	https://www.fatetherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-46.25%
EV Sales Forward	36.65x
EV/Sales	28.95x
FCF yield	-38.48%
P/B ratio	1.56x
P/S ratio	44.48x
PS Forward	56.3x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-2,207.47%
EBITDA Margin	-2,009.78%
Gross Profit	$-81.2M
Net Income	$-129.9M
Net Income Growth Quarters	5%
Net Income Growth Years	1%
Pretax Margin	-2,056.79%
Profit Per Employee	$-806,876
ROA	-25.29
Roa5y	-22.17
ROCE	-54.84
ROE	-55.5
Roe5y	-46.44
ROIC	-27.52

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	3.55%
Cagr1y	88.36%
Cagr3y	-18.55%
Cagr5y	-51.1%
EPS Growth Quarters	5
EPS Growth Years	1
Revenue Growth	-52.64x
Revenue Growth Q	-20.26x
Revenue Growth Years	0x
Revenue Growth3 Y	-64.13x
Revenue Growth5 Y	-30.89x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.02
Assets	$284.9M
Cash	$174.8M
Current Assets	$179.5M
Current Liabilities	$30.7M
Debt	$76.8M
Debt Equity	$0.43
Equity	$179.7M
Liabilities	$105.2M
Long Term Assets	$105.4M
Long Term Liabilities	$74.5M
Net Cash	$98M
Net Cash By Market Cap	$34.9
Net Cash Growth	-37.59%
Net Debt Equity	$-0.55
Tangible Book Value	$179.7M
Tangible Book Value Per Share	$1.55
WACC	14.22

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.85
Net Working Capital	$-21.2M
Quick ratio	5.75
Working Capital	$148.8M
Working Capital Turnover	$0.03

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.02%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	41.77%
1Y total return	88.28%
200-day SMA	1.55
3Y total return	-45.96%
50-day SMA	2.38
50-day SMA vs 200-day SMA	50over200
5Y total return	-97.2%
All Time High	121.2
All Time High Change	-98.01%
All Time High Date	2021-01-14
All Time Low	0.66
All Time Low Change	264.54%
All Time Low Date	2025-04-04
ATR	0.24
Beta	2.52
Beta1y	3.09
Beta2y	2.65
Ch YTD	145.3
High	2.55
High52	3.23
High52 Date	2026-07-13
High52ch	-25.39%
Low	2.4
Low52	0.91
Low52 Date	2025-08-11
Low52ch	164.84%
Ma50ch	1.09%
Premarket Change Percent	0
Premarket Price	$2.52
Premarket Volume	4,644
Price vs 200-day SMA	55.79%
RSI	43.04
RSI Monthly	43.83
RSI Weekly	56.77
Sharpe ratio	1.07x
Sortino ratio	1.96
Total Return	-1.02%
Tr YTD	145.3
Tr1m	11.57%
Tr1w	-13.31%
Tr3m	82.58%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	12
Analyst Count Top	5
Analyst Price Target Top	$5.4
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.26
Earnings Revenue Estimate	1,218,832x
Earnings Revenue Estimate Growth	-36.09x
Operating Income	$-138.3M
Operating margin	-2,190.1
Price target	$5.41
Price Target Change	$124
Price Target Change Top	$124

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	101,863,985%
Float Percent	87.39%
Shares Insiders	1.49%
Shares Institutions	54.78%
Shares Out	116,559,186
Shares Qo Q	0.66%
Shares Yo Y	1.02%
Short Float	7.3%
Short Ratio	1.54
Short Shares	6.38

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-129.6M
Average Volume	4,019,080.45x
Bv Per Share	1.55
CAPEX	$-5M
Ch10y	41.77
Ch1m	11.57
Ch1w	-13.31
Ch1y	88.28
Ch3m	82.58
Ch3y	-45.96
Ch5y	-97.2
Ch6m	99.17
Change	-4.37%
Change From Open	-4.37
Close	2.52
Days Gap	0
Depreciation Amortization	12,486,000
Dollar Volume	2,517,085.9
Earnings Date	2026-08-11
Earnings Time	amc
EBIT	$-139.4M
EBITDA	$-126.9M
EPS	$-1.09
F Score	1
FCF	$-108.1M
FCF EV Yield	-59.11x
FCF Per Share	$-0.93
Financing CF	5,490,000
Fiscal Year End	December
Founded	2,007
Investing CF	92,080,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-13
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	1.65
Ma150ch	45.88%
Ma20	2.8
Ma20ch	-13.87%
Net CF	-5,527,000
Next Earnings Date	2026-08-11
Open	2.52
Optionable	Yes
Position In Range	6.9
Post Close	2.41
Postmarket Change Percent	0.42
Postmarket Price	$2.42
Ppne	95,340,000
Pre Close	2.52
Price Date	2026-07-24
Ptbv Ratio	1.56
Relative Volume	0.26x
Revenue	6,316,000x
SBC By Revenue	339.96x
Share Based Comp	21,472,000
Tr6m	99.17%
Us State	California
Volume	1,044,434
Z Score	-7.88

Fate Therapeutics, Inc. (FATE)

Coverage state: Market snapshot only — no published research

Generate the first FATE analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · FATE

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All FATE indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on FATE

Frequently asked questions